Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies

被引:37
作者
Brannagan, TH [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Peripheral Neuropathy Ctr, Dept Neurol & Neurosci, New York, NY 10021 USA
关键词
D O I
10.1212/WNL.59.12_suppl_6.S33
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Intravenous immune globulin (IVIg) is considered an effective and safe treatment for autoimmune neuropathies, especially in comparison to the alternative treatments such as corticosteroids, chemotherapy, and plasmapheresis. Patients are frequently given a standard induction dose of 2 g/kg, which may be followed by maintenance therapy as needed. Mild infusion-related reactions are frequent but these can often be controlled by slowing the infusion rate or by symptomatic medications. Serious adverse effects are rare and can include thromboembolic events, renal failure, anaphylaxis, or septic meningitis. Patients with IgA deficiency are at risk for anaphylaxis. Immobility, increased serum viscosity, and preexisting vascular disease can increase the risk for thromboembolic events. Preexisting renal insufficiency or the use of sucrose-containing IVIg preparations can increase the risk for renal failure, and patients with migraine are at risk for development of aseptic meningitis. Screening patients for risk factors that predispose to development of adverse events may reduce the incidence of complications.
引用
收藏
页码:S33 / S40
页数:8
相关论文
共 90 条
[81]   Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome [J].
Turner, B ;
Wills, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (06) :790-791
[82]   TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
VANDENBERG, LH ;
KERKHOFF, H ;
OEY, PL ;
FRANSSEN, H ;
MOLLEE, I ;
VERMEULEN, M ;
JENNEKENS, FGI ;
WOKKE, JHJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 59 (03) :248-252
[83]   A RANDOMIZED TRIAL COMPARING INTRAVENOUS IMMUNE GLOBULIN AND PLASMA-EXCHANGE IN GUILLAIN-BARRE-SYNDROME [J].
VANDERMECHE, FGA ;
SCHMITZ, PIM .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (17) :1123-1129
[84]   INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY - CLINICAL AND LABORATORY CHARACTERISTICS ASSOCIATED WITH IMPROVEMENT [J].
VANDOORN, PA ;
VERMEULEN, M ;
BRAND, A ;
MULDER, PGH ;
BUSCH, HFM .
ARCHIVES OF NEUROLOGY, 1991, 48 (02) :217-220
[85]   RECURRENT ASEPTIC-MENINGITIS COMPLICATING INTRAVENOUS IMMUNOGLOBULIN THERAPY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY [J].
VERARAMIREZ, M ;
CHARLET, M ;
PARRY, GJ .
NEUROLOGY, 1992, 42 (08) :1636-1637
[86]   Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin [J].
Voltz, R ;
Rosen, FV ;
Yousry, T ;
Beck, J ;
Hohlfeld, R .
NEUROLOGY, 1996, 46 (01) :250-251
[87]   Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura [J].
Warrier, I ;
Bussel, JB ;
Valdez, L ;
Barbosa, J ;
Beardsley, DS ;
Grossi, M ;
Berkow, R ;
Rado, T ;
Siegel, R ;
Weinstein, R ;
Henry, D ;
Wallach, S ;
Weisman, S ;
Hoots, WK ;
Zeigler, Z .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (03) :197-201
[88]  
Wolberg AS, 2000, AM J HEMATOL, V65, P30, DOI 10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.3.CO
[89]  
2-A
[90]  
WOODRUFF RK, 1986, LANCET, V2, P217